Orthostatic Hypotension in Patients with Parkinson’s Disease and Atypical Parkinsonism

Seyed-Mohammad Fereshtehnejad and Johan Lökk

1 Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet, Novum 5th Floor, 141 86 Stockholm, Sweden
2 Firoozgar Clinical Research Development Center (FCRDC), Firoozgar Hospital, Iran University of Medical Sciences, Tehran 15937-48711, Iran
3 Department of Geriatric Medicine, Karolinska University Hospital, 141 86 Stockholm, Sweden

Correspondence should be addressed to Seyed-Mohammad Fereshtehnejad; sm.fereshtehnejad@ki.se

Received 15 October 2013; Accepted 11 December 2013; Published 2 February 2014

1. Introduction

Orthostatic hypotension (OH) is the most common symptom of cardiovascular autonomic dysfunction in parkinsonian patients [1, 2], which can affect both patients with idiopathic Parkinson's disease (IPD) and atypical parkinsonism (AP). In general, OH refers to a fall in systolic blood pressure of at least 20 mmHg and diastolic blood pressure of at least 10 mmHg on standing or head-up tilt [3]; its prevalence in PD varies between 9.6% and 58% [4, 5].

OH prevalence correlates with disease duration and could also be a result of PD medications, which lead to gait instability, generalised weakness, fatigue, a higher risk of falls, and reduced cognitive performance. It may herald the onset of PD years before motor features become apparent. Together with other nonmotor symptoms, OH may gradually and critically impact quality of life in parkinsonian patients [6, 7]. Although some original studies have been previously performed on this topic, there are still arguments and gap of knowledge on many aspects of OH from the prevalence to treatment strategies. Nowadays, OH causes a major management problem in parkinsonian patients, which necessitates further evaluation and improvement in our knowledge.

In attempting to address some of these knowledge gaps, this review aimed to summarise current evidences on different aspects of OH from epidemiology, aetiology, diagnosis, prognosis, and treatment. We searched relevant databases to find appropriate articles on OH in IPD and/or AP. For this purpose, major electronic medical databases were assessed including PubMed/MEDLINE and Embase up to February 2013. English-written original or review articles with keywords such as “Parkinson’s disease,” “atypical parkinsonism,” and “orthostatic hypotension” were searched for relevant evidences. We addressed different issues such as OH definition, epidemiologic characteristics, pathophysiology, testing and diagnosis, risk factors for symptomatic OH, OH as an early sign of IPD, prognosis, and treatment options of OH in parkinsonian syndromes. Symptomatic OH is present in up to 30% of IPD, 80% of multiple system atrophy (MSA), and 27% of other AP patients. OH may herald the onset of PD before cardinal motor symptoms and our review emphasises the importance of its timely diagnosis (even as one preclinical marker) and multifactorial treatment, starting with patient education and lifestyle approach. Advancing age, male sex, disease severity, and duration and subtype of motor symptoms are predisposing factors. OH increases the risk of falls, which affects the quality of life in PD patients.
3. Results

Based on the literature review about the main topic of interest, orthostatic hypotension in parkinsonian patients, the following aspects were identified to have both research importance and clinical implications.

3.1. Definition. Based on the agreement of the Consensus Committee of the American Autonomic Society and the American Academy of Neurology, OH has been defined as a sustained fall of ≥20mmHg in systolic or ≥10mmHg in diastolic blood pressure within 3 min of active standing or head-up tilt to at least 60°. In the recent revision of the consensus statement, a systolic fall of 30mmHg was defined as OH for patients with an abnormally high supine blood pressure [3]. However, some symptomatic patients may have a much greater fall in blood pressure on standing [1].

It must be considered that some PD patients might have the underlying pathology of OH but no apparent symptoms. Findings from a transcranial Doppler (TCD) study show that the impairment of cerebral vasomotor reactivity (VMR) is even more common than detectable OH in PD patients [8]. The prevalence rate of asymptomatic OH in PD has been estimated as 20–50% in another published report. This study also showed that OH might occur even after the currently recommended duration of 3 min for tilt testing [9]. Some researchers now impugn the accuracy of the current criteria for OH definition in which blood pressure is examined after 3 min of gravitational stimulus [9]. Current criteria may miss OH in some parkinsonian patients as symptoms of OH secondary to autonomic failure characteristically appear after tilting or standing, which are relieved upon sitting or lying flat [10].

3.2. Symptoms. It is not still quite clear why OH is asymptomatic in a subgroup of PD patients. However, OH may present some nonspecific general symptoms in parkinsonian patients consisting of giddiness, dizziness, empty-headedness, visual disturbances, unconsciousness, weakness, falls, syncope, and even nausea or pain, mostly while standing [11, 12]. It has already been demonstrated that some OH symptoms such as dizziness, visual disturbances, impaired cognition, and fainting occur when the decline in blood pressure induces impairment in cerebral perfusion [13], and causes a failure in cerebrovascular autoregulation [14].

In one recently published paper, Ha et al. reported that older age, more advanced disease, longer duration of PD, and a wider range of sitting blood pressure increased the risk of symptomatic OH [15]. Predictably, symptomatic OH is more common in PD patients with posture and gait instability phenotype compared to those with the tremor-dominant variety of the disease [16, 17].

3.3. Diagnosis. Nowadays, several methods are used to diagnose and/or assess OH in parkinsonian patients such as physical examination, neuroimaging techniques, and subjective or objective scales and questionnaires (Table 2).

During physical examination, OH is diagnosed using a gravitational stimulus such as tilting or standing. Physicians used to assess OH by recording the changes in blood pressure using a sphygmomanometer after the PD patient had been standing for 3 min from the supine position. However, in a research setting, OH is more often checked by means of a tilt table [9]. Demonstrating the fact that OH is more likely to occur after tilting than standing [15], this type of clinical examination may result in underestimation of OH in PD patients.

In head-up tilt-table testing (HUT), the subjects are tilted to a 60-degree upright position within 15 seconds using a head-up tilt table. As a simple, noninvasive, and informative method, the tilt-table test is performed by having the patient lie flat on a special bed or table with special safety belts and a footrest while monitoring for blood pressure is done. The bed or table is then elevated to an almost standing position (60- to 80-degree vertical angle) to simulate the patient standing up from a lying position. The blood pressure is measured during the test to evaluate its probable drop during this positional change. Patients are defined as having OH if the standing systolic blood pressure falls by at least 20mmHg or ≥10mmHg occurred in diastolic blood pressure [3]. The Valsalva manoeuvre is another physical examination that can be used to assess autonomic function in haemodynamics in PD patients. It has been shown that findings from this manoeuvre are highly sensitive and reproducible for the assessment of arterial baroreflex [18], the function which is attenuated in PD. In the Valsalva manoeuvre, patients are asked to exhale into a mouthpiece at an expiratory pressure of 40 mmHg for 15 seconds. Blood pressure and RR intervals (from the corresponding ECG) are measured during the manoeuvre by tonometry, using a noninvasive blood pressure monitoring system. The duration of the Valsalva manoeuvre is divided into four phases and several indexes, including the baroreceptor reflex sensitivity (BRS), which are measured within specific phases. Analyses of data on blood pressure, RR interval, and BRS allow conclusions to be drawn about the autonomic haemodynamics of the patients [19–21]. Spectral analysis of the RR interval and systolic blood pressure are commonly used to measure cardiac autonomic activity, representing cardiac sympathovagal interaction, and their findings are variably impaired in PD [22]. Even more, these findings of heart rate variability may be an early manifestation of PD, which might be useful in the assessment of the rate of

PUBMED/MEDLINE and EMBASE up to February 2013. Combined search terms such as “Parkinson’s disease,” “atypical parkinsonism,” and “orthostatic hypotension” were entered to look for English-written original or review papers. Afterwards, articles were retrieved, and references were also searched for relevant manuscripts containing the above-mentioned keywords. We consider only published or in-press peer-reviewed articles to provide qualified evidences for this narrative review paper. After reviewing of the relevant papers with different types such as review articles, original researches, and case reports, current knowledge on this topic was categorised and presented in several sections consisting of “definition,” “symptoms,” “epidemiology,” “pathophysiology,” “diagnosis,” “prodromal OH,” “predisposing factors,” “prognosis,” and “treatment.”
disease progression and the efficacy of medication [23]. Using spectral analysis of RR interval and systolic blood pressure, one study showed reduced absolute values of both the high- and low-frequency spectral components in PD patients compared with age-matched healthy subjects [24]. Another study demonstrated a higher systolic blood pressure, lower low- to high-frequency ratio and low-frequency systolic blood pressure in PD patients with symptomatic OH compared to control subjects using spectral analysis [25]. Interestingly, they also reported that the increase in heart rate, low- to high-frequency ratio, and low-frequency systolic blood pressure was blunted in PD patients with or without symptomatic OH compared to the control group during tilt [25]. These findings further confirm that spectral analysis of heart rate may be useful in early diagnosis of orthostatic intolerance regardless of a recognized orthostatic hypotension in the history of PD patients [25].

As shown in the Movement Disorders Society Task Force report, OH is usually contained within the list of questions that record either the whole nonmotor or dysautonomia symptoms. From another point of view, while some scales provide information on the severity and/or frequency of OH-related symptoms, others only ask for the presence or absence of OH symptoms [26]. Table 2 lists the names of well-validated scales that include items to record the severity and/or frequency of OH-related symptoms. Other than the level of symptoms, it must be noted that not all OH-related symptoms are recorded in all of these scales and the medical terminology applied to express them might also differ. For instance, the Orthostatic Grading Scale [27] and L-threo-DOPS [28, 29] measure “maximal standing time,” whereas other scales such as the AUTonomic SCale for Outcomes in PArkinson’s Disease (SCOPA-AUT) [30] and the Composite Autonomic Symptom Scale (COMPASS) [31] directly asked for “faintness” or “syncope.” Faintness, dizziness, and light-headedness are the most frequent orthostatic symptoms that are recorded in most of these rating scales; however, “decreased hearing” is only rated in the scale used by Senard et al. [32] and “difficulty thinking” is only measured by the SCOPA-AUT [30] and the COMPASS [31]. More detailed comparisons are presented in the Movement Disorders Society Task Force report [26]. Conclusively, they recommended SCOPA-AUT [30] and COMPASS [31] as the clinimetrically proved scales; however, other questionnaires are also suggested as valid screening tools for OH in PD. As a well-known commonly used questionnaire, the Unified Parkinson’s Disease Rating Scale (UPDRS) has only one item addressing OH. This item is in the part IV of the UPDRS scale on “complications of therapy” and was reported as a low sensitivity screening tool for OH [26]. In addition to the scales listed in Table 2, the Unified Multiple System Atrophy Rating Scale (UMSARS) is also applied to assess different symptoms in MSA, including autonomic problems as a semiquantitative tool [33], but this has never been used in IPD patients [26].

According to underlying pathophysiology of OH in PD, nuclear neuroimaging techniques are applicable in suspected patients. Almost all patients with PD and OH have markedly reduced sympathetic noradrenergic innervation of the left ventricular myocardium, which could be evaluated with single-photon emission computed tomography and $^{123}$I-meta-iodobenzylguanidine (MIBG) uptake. Interestingly, this finding is not seen in MSA patients with OH and could be helpful for differential diagnosis [34, 35]. In order to perform cardiac $^{123}$I-MIBG scintigraphy, firstly the tracer $^{123}$I-MIBG is injected intravenously in an amount of 111 MBq for the patients. Then, region-of-interest (ROI) analysis is applied to evaluate the $^{123}$I-MIBG uptake, and the ratio of the average pixel count in the heart to that in the mediastinum is calculated and reported after the early (15 min) and delayed (3 hour) phases [36]. This parameter is used to judge the cardiac sympathetic noradrenergic innervation.

Another paraclinical assessment tool that has potential application in the study of OH in parkinsonian patients is transcranial Doppler (TCD) ultrasonography. As a noninvasive technique, TCD measures blood flow velocities of the main intracranial vessels, such as the middle cerebral artery, and is a broadly applied tool for evaluating the cerebrovascular reactivity in neurological disorders including PD. To evaluate dysautonomia, vasomotor reactivity, and cerebral haemodynamics in parkinsonian patients, TCD is usually used in combination with one of the standardised methods applied to activate the sympathetic adrenergic innervation system. These methods include the tilt-table test [37], head-up tilt test [38], thigh cuff release test [39], carbon dioxide test [8], Diamox injection [40], or the cold pressure test (CPT) [41, 42]. These techniques make it possible to identify even asymptomatic OH patients.

3.4. Epidemiology. So far, many epidemiologic studies have been performed to estimate the prevalence rate of OH in PD or other parkinsonian syndromes. One important aspect of these epidemiologic surveys refers to study design. While most of these studies have been designed as cross-sectional projects to assess the point prevalence of OH, there are a few longitudinal cohorts, which were able to report the incidence rate of OH during disease followup. The point prevalence shows a snapshot of the proportion of PD patients with OH that exists in a defined PD population at one specific time point. Therefore, it does not contain any further information on the relationship between OH incidence and disease progression.

In one longitudinal cohort study, almost 48% of PD patients represented symptomatic OH during a 20-year follow-up period [43]. Expectedly, the point prevalence estimations of cross-sectional reports are often lower. In general, published estimates of OH in idiopathic PD range between 9.6% and 47% [4, 32, 44, 45] and are even as high as 58% [5]. Recently, in a meta-analysis of 25 recruited studies, a pooled point prevalence of 30.1% (95% CI: 22.9% to 38.4%) was estimated for OH in patients with PD [46].

The discrepancies in prevalence rate estimation of OH in PD stem from several factors such as selection criteria, study population, study design (cross-sectional versus longitudinal), the criteria used to define OH, and the method of BP measurement [47]. The most important factor refers to the diagnostic methods and/or criteria that are applied to define OH in a PD population. For instance, not all studies have used
Table 1: Prevalence of symptomatic orthostatic hypotension in different types of parkinsonian syndromes.

| Type of Parkinsonian syndromes      | Reference | Sample size | Type of evidence | Prevalence rate (%) |
|-------------------------------------|-----------|-------------|------------------|---------------------|
| Idiopathic Parkinson’s disease (IPD)| [46]      | 5070        | Meta-analysis    | 30.1                |
|                                     | [15]      | 1125        | Cross-sectional  | 18                  |
|                                     | [45]      | 3414        | Multicentre registry | 10.6              |
|                                     | [51]      | 1130        | Longitudinal     | 14.7                |
| Multiple system atrophy (MSA)       | [15]      | 26          | Cross-sectional  | 81                  |
|                                     | [51]      | 34          | Longitudinal     | 54.6                |
| Progressive supranuclear palsy (PSP)| [15]      | 26          | Cross-sectional  | 11                  |
|                                     | [51]      | 30          | Longitudinal     | 13.3                |
| Corticobasal degeneration (CBD)     | [15]      | 14          | Cross-sectional  | 7                   |
|                                     | [51]      | 11          | Longitudinal     | 0                   |
| Vascular parkinsonism (VP)          | [15]      | 38          | Cross-sectional  | 26                  |
|                                     | [51]      | 83          | Longitudinal     | 18.3                |
| Dementia with Lewy bodies (DLB)     | [15]      | 32          | Cross-sectional  | 31                  |
|                                     | [51]      | 14          | Longitudinal     | 21.4                |
|                                     | [52]      | 26          | Cohort           | 42                  |

Even if most of the studies used this definition, the examination setting, such as tilting angle, might also differ, which could be considered another source of diversity. While some researchers used 45 degrees to ensure that the participants could tolerate the full course of head-up tilting [48], an angle of 60 to 70 degrees of tilting is usually required to provoke OH with a higher diagnostic value [49, 50]. As a consequence, not only do the prevalence data vary between studies, but also associated risk factors and probable effects of OH during the PD course are also dependent on the exact definitions adhered in that specific survey.

Rather than idiopathic PD, available data regarding the frequency of OH in atypical parkinsonian syndromes are not sufficient and most of the reports lack appropriate sample size. Table 1 summarises the frequency rates of OH in different types of parkinsonian syndromes estimated from some of the important recent surveys on this issue. Although the number of recruited patients with atypical PD is considerably lower than IPD and a definitive conclusion is limited, it seems that OH is most frequent in MSA. The prevalence of OH varies from as low as 0–7% in CBD, to the higher rates in PSP, VP, DLB, and IPD and to as high as 81% in MSA (Table 1). This noticeable high-frequency rate of symptomatic OH in MSA could present even in the early stage of the disease and is expected due to the well-known autonomic failure in MSA [15].

3.5. Pathophysiology. In general, a degree of damage to the postganglionic sympathetic efferences is suggested as the main cause of dysautonomia in PD, while these postganglionic lesions are not found in patients with MSA [57]. Based on current evidences, three main components work together to induce OH in PD, including noradrenergic denervation in both cardiac and extracardiac regions and arterial baroreflex failure as the third determinant [58]. This underlying pathophysiology is believed to act independently of the nigrostriatal dopamine depletion [58, 59]. Although direct evidences come from dementia with Lewy bodies, the myocardial sympathetic denervation was shown to associate with decreased vesicular uptake of catecholamines [60], in a process that might start years before motor involvement in PD. This pathology is highly typical as all of the PD patients with OH noticeably suffer from reduced sympathetic noradrenergic innervation of the left ventricular myocardium [61], which demonstrates a strong link between sympathetic cardiac denervation and OH in PD. Even Jain and Goldstein
recommend that one can exclude PD diagnosis in central neurodegenerative disorder with OH when normal noradrenergic innervation is reported for myocardium in imaging evaluations [58]. However, one study using positron emission tomography (PET) scanning showed that this denervation is profound in the heart but also could be detected in extracardiac organs such as the renal cortex and thyroid gland [62].

The third part of the pathophysiological puzzle of OH in PD, arterial baroreflex failure, involves both the cardiovagal and sympathoneural limbs, which results in an obviously lower extent of decrease in the time between heartbeats (interbeat interval) during the Valsalva manoeuvre [58]. This pathophysiological base could also induce postprandial hypotension, instability of blood pressure, supine hypertension, and possibly fatigue and exercise intolerance [58]. As a consequence, coexistent supine hypertension and orthostatic hypotension may occur in some PD patients resulting from the malfunctioning of baroreflex system. Therefore, clinicians should be aware of this possibility in PD patients presenting symptoms of orthostatic intolerance, especially in those with a large supine standing fluctuation in blood pressure [63].

From a broader point of view, the baseline process of synuclein accumulation in intraneuronal Lewy bodies of the limbic cortex, frontal neocortical areas [64, 65], and the peripheral autonomic nervous system [66] could provide evidence to explain the more rapid cognitive decline observed in PD patients suffering from OH [66, 67].

Despite the fact that the underlying cause for OH is independent of dopaminergic deficit, PD-related medications such as selegiline and dopamine agonists also contribute to the OH [68–70]. OH is further exacerbated by the use of dopaminergic drugs, such as levodopa, which has vasodilative effects via the renal and splanchnic vasculature [71, 72]. Consequently, selegiline may also augment the central hypotensive effect of levodopa by increasing dopamine availability through MAO-B inhibition [73], and it was shown that the withdrawal of selegiline suppresses the orthostatic blood pressure reaction in advanced PD patients [68].

3.6. Prodromal OH. OH is usually considered a symptom that typically develops and progresses during the later course of PD. Nowadays, it is believed that dysautonomia may herald the onset of PD even before motor symptoms manifest [15]. Also, OH can even precede PD diagnosis in some patients, which outlines OH as a potential prodromal marker in parkinsonian syndromes [74]. It has been shown that up to 60% of PD patients with OH had already suffered from the symptom in the early phase of PD [75]. Although prodromal OH in parkinsonian syndromes is mostly believed to be in favour of MSA due to its well-known autonomic failure [76–78], rising evidences suggest that this feature could precede PD as well. Even in some postmortem studies, early OH was recorded in autopsy-proven PD patients misdiagnosed as MSA [79, 80]. On the other hand, another study showed that one-third of pathologically proven MSA patients were mislabelled as PD during their life [81]. Dealing with the exact timing for the beginning of OH is always the subject of debate, and there is also a lack of pathologic postmortem evidence to differentiate between IPD and MSA. However, a neuroimaging technique that traces 6-[18F]fluorodopamine-derived radioactivity in the cardiac sympathetic system could assist in this issue. Based on evidences from postmortem studies, a marked decrease in its radioactivity throughout the left ventricular myocardium showing loss of postganglionic sympathetic noradrenergic nerves may exclude MSA [75].

Pathologically, this is now a question of interest whether loss of cardiac sympathetic nerves could precede the main nigrostriatal dopamine depletion in PD or not. If so, then symptoms such as OH could clinically present or at least be discovered years before the motor features of the disease start. Based on the Braak schema [82] of the pathologic development of PD, cardiac sympathetic denervation could be even found in PD patients without OH during the early phase of disease [58]. Although there is a gap of large sample size evidences, the idea has been proven in some case studies. By neuroimaging assessment, cardiac sympathetic denervation has been shown in one patient four years before PD onset [83] and in another with symptomatic OH five years before motor features [84]. More interestingly, such damage in cardiac sympathetic nervous system was reported in patients with OH who later developed a parkinsonism syndrome [75].

3.7. Predisposing Factors. To date, several factors have been found to relate to the presence of OH in PD, such as advancing age, male gender, disease severity or duration [36, 85–87], and clinical subtype of motor symptoms [22, 88]. PD duration has been shown to be a stronger determinant for OH compared to the severity of disease [89]. In addition, there are number of general predisposing factors for OH, which are not specific for PD. These factors include dehydration, deconditioning, poor nutrition, and aging-related changes [1]. Heat, food ingestion, alcohol, exercise, and activities that increase intrathoracic pressure (e.g., defecation and coughing) [57] must be also taken into consideration while evaluating a PD patient with OH.

Some of the antiparkinsonian medications could either cause or worsen OH. Levodopa could induce OH by reducing the stroke volume, cardiac output, and systemic vascular resistance [9, 90]. As previously mentioned, selegiline and dopamine agonists also could play a role in causing OH in PD patients [68–70]. However, evidences regarding the role of PD medication and OH are controversial. In one study on 55 PD patients, OH was not related to either dopaminergic medication such as levodopa or ergot and nonergot dopamine agonists [36]. Apart from PD-specific medications, some other drugs could predispose OH in PD patients, such as the chronic use of tricyclic antidepressants; antihypertensive agents and diuretics; vasodilators like nitroglycerin, hydralazine, calcium channel blockers, and tizanidine (Zanaflex) [1]. A recent study on 103 PD patients showed that polypharmacy, intake of diuretics or amantadine increase the risk of OH after statistical adjustment for confounding factors, whereas entacapone was found to be a protective factor [91]. Whether as a proxy for several comorbidities in frail elderly PD patients or due to pharmaceutical interaction, polypharmacy seems to be an important determinant to increase the risk of OH. Even a direct correlation has been
shown between the number of medications and episodes of OH in elderly as well as PD patients [91, 92].

3.8. Prognosis. As can be seen from general evidences, OH is associated with increased mortality and morbidities in middle-aged adults and the elderly [93, 94] including stroke and cognitive decline [95].

Specifically in PD, OH is associated with postural sway [47] and an increased risk of falls [96]. There are also evidences suggesting that impaired attention [2] and visual episodic memory [97] are more frequent in PD patients suffering from OH. In one study on 44 PD patients, the presence of OH was shown to be related to greater levels of motor disability (specifically gross motor function), more difficulty with tasks that require postural changes or prolonged mobility, and a decline in cognitive function with lower MMSE score [98]. However, the effect of OH on cognition in PD patients is still conflicting, as some reports show no marked impairment of cognitive function when OH is present [44, 99]. Overall, it seems important to consider which subset of cognition is of interest; as can be seen from the aforementioned evidences, visual episodic memory and social cognition are more likely to be impaired in PD patients with OH.

It has already been demonstrated that OH considerably impairs the quality of life in PD patients [100], via an effect that could be implied either directly or indirectly through cognitive impairment, frequent falls, or other accompanied symptoms. The effect of OH on quality of life in parkinsonian patients is a two-dimensional causal relationship, as it has been shown that early diagnosis and symptomatic treatment of OH can greatly improve the quality of life in PD patients and, even in the case of pathologically elevated blood pressure, probably decrease cardiovascular mortality [101].

3.9. Treatment. Treatment of OH should be multifactorial, always starting with patient education and lifestyle approaches [15]. Hence, physical activity is a major cornerstone in OH treatment and patients must be urged to move and exercise to their full capacity. When moving from sitting or lying down, slowness in movements is prompted to avoid a fall in blood pressure [102]. Patients should change their eating habits from three meals a day to more frequent, smaller, and less carbohydrate-based meals, as well as having adequate hydration with at least 2 litres/day [103]. An increased intake of salt aiming at more than 8 grams daily can be tried, thereby increasing the plasma volume and blood pressure. By using compressive long stockings, a change in blood pooling from the lower to the upper parts of the body might elevate blood pressure and have some positive subjective effects on orthostatic coexisting unsteadiness and dizziness [104]. Raising the head of the bed on blocks, thereby improving the endocrinological regulatory system, should be tried before initiating pharmacological treatment [105]. When it comes to pharmacological treatment, blood pressure lowering drugs should first be reassessed and/or stopped. Naturally, the total dopaminergic load must be also reevaluated and, if possible, reduced, as this affects blood pressure. This being done with insufficient effects, sympathomimetic drugs like dihydroergotamine and/or etilefrine can be introduced in increasing/high doses [106]. If these provide unsatisfactory effects, the mineralocorticoid fludrocortisone, 1-2 mg daily, can be tried with some caution due to a risk of causing oedema following its plasma volume expansion [78]. The alpha-1-agonist midodrine in doses of 5–40 mg daily can be another quite powerful option, as can the use of the noradrenaline-like prodrug droxidopa [107]. There are also some reports of the antidiuretic hormone desmopressin and the peripheral dopamine blocker domperidone having effects on OH in PD patients [108].

However, the coexistence of OH and supine hypertension presents some additional problems when treating OH in affected PD patients. Using blockers of alpha-2 adrenergic receptors such as yohimbine, which increases the release of norepinephrine and dopamine, can worsen supine hypertension. The same issue also exists when an indirectly acting sympathomimetic amine such as tyramine is given with a monoamine oxidase inhibitor [58].

4. Conclusion

This review summarises some of the important evidences, discrepancies, and issues on different aspects of OH in parkinsonian patients, such as epidemiology, pathophysiology, diagnosis, predisposing factors, prognosis, and treatment. Studies show that OH is quite common in PD and its timely diagnosis may need further assessments (such as paraclinical evaluations and/or blood pressure monitoring) beyond the recommended 3 min postural challenge that is currently used in clinical practice, as this could potentially miss some asymptomatic cases. Physicians must consider evaluating blood pressure in PD patients not only in the conventional sitting posture but also in different positional settings to be able to detect OH.

Our present knowledge of OH in parkinsonian syndromes highlights its important role in better understanding of PD aetiology, as well as its marked effect on quality of life of the parkinsonian patients. Educating patients and their families about OH symptoms could help in the early detection and better management of OH, which may improve their quality of life. There are still huge gaps in appropriate evidences and knowledge of several aspects of OH in parkinsonian patients, which emphasises the need for further studies on this topic. Inevitably, any progress in our knowledge about predisposing factors, diagnostic tools, and treatment options for OH might assist in the early detection of this potentially treatable cause to prevent falls in elderly parkinsonian patients. However, even based on current evidences that show the negative impacts of this common problem on different aspects of PD-specific quality of life (i.e., gross motor, balance, and cognitive function), it seems logical to routinely screen PD patients for OH.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.
References

[1] D. Robertson, “The pathophysiology and diagnosis of orthostatic hypotension,” Clinical Autonomic Research, vol. 18, supplement 1, pp. 2–7, 2008.

[2] C. Peralta, M. Stamper-Kountchev, E. Karner et al., “Orthostatic hypotension and attention in Parkinson’s disease with and without dementia,” Journal of Neural Transmission, vol. 114, no. 5, pp. 585–588, 2007.

[3] R. Freeman, W. Wieling, F. B. Axelrod et al., “Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome,” Autonomic Neuroscience: Basic and Clinical, vol. 161, no. 1–2, pp. 46–48, 2011.

[4] S. Papapetropoulos, C. Paschalis, A. Athanassiadou et al., “Clinical phenotype in patients with α-synuclein Parkinson’s disease living in Greece in comparison with patients with sporadic Parkinson’s disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 70, no. 5, pp. 662–665, 2000.

[5] P. A. Low, “Prevalence of orthostatic hypotension,” Clinical Autonomic Research, vol. 18, supplement 1, pp. 8–13, 2008.

[6] D. A. Gallagher, A. J. Lees, and A. Schrag, “What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them?” Movement Disorders, vol. 25, no. 15, pp. 2493–2500, 2010.

[7] M. Politis, K. Wu, S. Molloy, P. G. Bain, K. R. Chaudhuri, and P. Piccini, “Parkinson’s disease symptoms: the patient’s perspective,” Movement Disorders, vol. 25, no. 11, pp. 1646–1651, 2010.

[8] B. Zamani, M. Mehrabani, S. M. Fereshtehnejad, and M. Rohani, “Evaluation of cerebral vasomotor reactivity in Parkinson’s disease: is there any association with orthostatic hypotension?” Clinical Neurology and Neurosurgery, vol. 113, no. 5, pp. 368–372, 2011.

[9] J. Jamnadas-Khoda, S. Koshy, C. J. Mathias, U. B. Muthane, M. Ragothaman, and S. K. Dodabalapur, “Are current recommendations to diagnose orthostatic hypotension in Parkinson’s disease satisfactory?” Movement Disorders, vol. 24, no. 12, pp. 1747–1751, 2009.

[10] C. H. Gibbons and R. Freeman, “Delayed orthostatic hypotension: a frequent cause of orthostatic intolerance,” Neurology, vol. 67, no. 1, pp. 28–32, 2006.

[11] K. M. Bleasdale-Barr and C. J. Mathias, “Neck and other muscle pains in autonomic failure: their association with orthostatic hypotension,” Journal of the Royal Society of Medicine, vol. 91, no. 7, pp. 355–359, 1998.

[12] L. D. Wood, J. J. Neumiller, S. M. Setter, and E. K. Dobbins, “Clinical review of treatment options for select nonmotor symptoms of Parkinson’s disease,” The American Journal Geriatric Pharmacotherapy, vol. 8, no. 4, pp. 294–315, 2010.

[13] W. L. Ooi, M. Hossain, and L. A. Lipsitz, “The association between orthostatic hypotension and recurrent falls in nursing home residents,” The American Journal of Medicine, vol. 108, no. 2, pp. 106–111, 2000.

[14] V. Novak, P. Novak, J. M. Spies, and P. A. Low, “Autoregulation of cerebral blood flow in orthostatic hypotension,” Stroke, vol. 29, no. 1, pp. 104–111, 1998.

[15] A. D. Ha, C. H. Brown, M. K. York, and J. Jankovic, “The prevalence of symmetrical orthostatic hypotension in patients with Parkinson’s disease and atypical parkinsonism,” Parkinsonism and Related Disorders, vol. 17, no. 8, pp. 625–628, 2011.

[16] L. M. Alcock, R. A. Kenny, and D. J. Burn, “Clinical phenotype of subjects with Parkinson’s disease orthostatic hypotension: autonomic symptom and demographic comparison,” Movement Disorders, vol. 21, no. 11, pp. 1851–1855, 2006.

[17] Assessment and management of orthostatic hypotension in Parkinson’s disease,” Annals of Indian Academy of Neurology, vol. 14, supplement 1, pp. S17–S18, 2011.

[18] J. Kautzner, J. E. K. Hartikainen, J. A. Camm, and M. Malik, “Arterial baroreflex sensitivity assessed from phase IV of the Valsalva maneuver,” The American Journal of Cardiology, vol. 78, no. 5, pp. 575–579, 1996.

[19] H. Oka, S. Mochio, K. Onouchi, M. Morita, M. Yoshioka, and K. Inoue, “Cardiovascular dysautonomia in de novo Parkinson’s disease,” Journal of the Neurological Sciences, vol. 241, no. 1–2, pp. 59–65, 2006.

[20] H. Oka, M. Yoshioka, M. Morita, S. Mochio, and K. Inoue, “Cardiac sympathetic dysfunction in Parkinson’s disease—relationship between results of 123I-MIBG scintigraphy and autonomic nervous function evaluated by the Valsalva maneuver,” Clinical Neurology, vol. 43, no. 8, pp. 465–469, 2003.

[21] H. Oka, S. Mochio, and K. Inoue, “Relation between autonomic dysfunction and progression of Parkinson’s disease,” Clinical Neurology, vol. 41, no. 6, pp. 283–288, 2001.

[22] T. H. Haapaniemi, V. Pursiainen, J. T. Korpelainen, H. V. Huikuri, K. A. Sotaniemi, and V. V. Myllylä, “Ambulatory ECG and analysis of heart rate variability in Parkinson’s disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 70, no. 3, pp. 305–310, 2001.

[23] “Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task force of the European society of cardiology and the North American society of pacing and electrophysiology,” European Heart Journal, vol. 17, no. 3, pp. 354–381, 1996.

[24] M. Kallio, T. Haapaniemi, J. Turkka et al., “Heart rate variability in patients with untreated Parkinson’s disease,” European Journal of Neurology, vol. 7, no. 6, pp. 667–672, 2000.

[25] F. Barbic, F. Perego, M. Canesi et al., “Early abnormalities of vascular and cardiac autonomic control in Parkinson’s disease without orthostatic hypotension,” Hypertension, vol. 49, no. 1, pp. 120–126, 2007.

[26] A. Pavy-Le Traon, G. Amarenco, S. Duerr et al., “The movement disorders task force review of dysautonomia rating scales in Parkinson’s disease with regard to symptoms of orthostatic hypotension,” Movement Disorders, vol. 26, no. 11, pp. 1985–1992, 2011.

[27] C. Schrezenmaier, J. A. Gehrking, S. M. Hines, P. A. Low, L. M. Benrud-Larson, and P. Sandroni, “Evaluation of orthostatic hypotension: relationship of a new self-report instrument to laboratory-based measures,” Mayo Clinic Proceedings, vol. 80, no. 3, pp. 330–334, 2005.

[28] C. J. Mathias, “L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience,” Clinical Autonomic Research, vol. 18, supplement 1, pp. 25–29, 2008.

[29] C. J. Mathias, J. Senard, S. Braune et al., “L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multicenter, dose-ranging study in multiple system atrophy and pure autonomic failure,” Clinical Autonomic Research, vol. 11, no. 4, pp. 235–242, 2001.

[30] M. Visser, J. Marinus, A. M. Stiggelbout, and J. J. van Hilten, “Assessment of autonomic dysfunction in Parkinson’s disease:...
D. N. Tipre and D. S. Goldstein, "Cardiac and extracardiac sympathetic denervation in Parkinson's disease with orthostatic hypotension and in pure autonomic failure," *Journal of Nuclear Medicine*, vol. 46, no. 11, pp. 1775–1781, 2005.

J. E. Naschitz, G. Slobodin, N. Elias, and I. Rosner, "The patient with supine hypertension and orthostatic hypotension: a clinical dilemma," *Postgraduate Medical Journal*, vol. 82, no. 966, pp. 246–253, 2006.

D. Aarsland, R. Perry, A. Brown, J. P. Larsen, and C. Ballard, "Neuropathology of dementia in Parkinson's disease: a prospective, community-based study," *Annals of Neurology*, vol. 58, no. 5, pp. 773–776, 2005.

H. Apaydin, J. E. Ahlskog, J. E. Parisi, B. F. Boeve, and D. W. Dickson, "Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response," *Archives of Neurology*, vol. 59, no. 1, pp. 102–112, 2002.

W. Poewe, "Dysautonomia and cognitive dysfunction in Parkinson's disease," *Movement Disorders*, vol. 22, supplement 17, pp. S374–S378, 2007.

S. Elmstähl and I. Rosén, "Postural hypertension and EEG variables predict cognitive decline: results from a 5-year follow-up of healthy elderly women," *Dementia and Geriatric Cognitive Disorders*, vol. 8, no. 3, pp. 180–187, 1997.

V. Pursiainen, T. J. Korpelainen, H. T. Haapaniemi, A. K. Kujawa, S. Leurgans, R. Raman, L. Blasucci, and C. G. S. Elmståhl and I. Rosén, "Postural hypotension and EEG variables predict cognitive decline: results from a 5-year follow-up of healthy elderly women," *Dementia and Geriatric Cognitive Disorders*, vol. 8, no. 3, pp. 180–187, 1997.

V. Pursiainen, T. J. Korpelainen, H. T. Haapaniemi, A. K. Kujawa, S. Leurgans, R. Raman, L. Blasucci, and C. G. S. Elmståhl and I. Rosén, "Postural hypotension and EEG variables predict cognitive decline: results from a 5-year follow-up of healthy elderly women," *Dementia and Geriatric Cognitive Disorders*, vol. 8, no. 3, pp. 180–187, 1997.

K. Kujawa, S. Leurgans, R. Raman, L. Blasucci, and C. G. Goetz, "Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease," *Archives of Neurology*, vol. 57, no. 10, pp. 1461–1463, 2000.

T. H. Haapaniemi, M. A. Kallio, J. T. Korpelainen et al., "Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease," *Journal of Neurology*, vol. 247, no. 11, pp. 868–874, 2000.

J. Jankovic and M. Stacy, "Medical management of levodopa-associated motor complications in patients with Parkinson's disease," *CNS Drugs*, vol. 21, no. 8, pp. 677–692, 2007.

A. D. Mosnaim, R. Abiola, M. E. Wolf, and L. C. Perlmutter, "Etiology and risk factors for developing orthostatic hypotension," *The American Journal of Therapeutics*, vol. 17, no. 1, pp. 86–91, 2010.

V. V. Mylläry, K. A. Sotaniemi, J. A. Vuorinen, and E. H. Heinonen, "Selegiline as a primary treatment of Parkinson's disease," *Acta Neurologica Scandinavica, Supplementum*, vol. 84, no. 136, pp. 70–72, 1991.

D. D. Truong and E. C. Wolters, "Recognition and management of Parkinson's disease during the premotor (prodromal) phase," *Expert Review of Neurotherapeutics*, vol. 9, no. 6, pp. 847–857, 2009.

D. S. Goldstein, "Orthostatic hypotension as an early finding in Parkinson's disease," *Clinical Autonomic Research*, vol. 16, no. 1, pp. 46–54, 2006.

D. J. Gelb, E. Oliver, and S. Gilman, "Diagnostic criteria for Parkinson disease," *Archives of Neurology*, vol. 56, no. 1, pp. 33–39, 1999.

E. Martignoni, C. Pacchetti, L. Godi, G. Micieli, and G. Nappi, "Autonomic disorders in Parkinson's disease," *Journal of Neural Transmission, Supplement*, no. 45, pp. 11–19, 1995.

J. M. Senard, C. Brefel-Courbon, O. Rascol, and J. Montastruc, "Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management," *Drugs and Aging*, vol. 18, no. 7, pp. 495–505, 2001.

E. E. Benarroch, A. M. Schmeichel, and J. E. Parisi, "Involvement of the ventrolateral medulla in parkinsonism with autonomic failure," *Neurology*, vol. 54, no. 4, pp. 963–968, 2000.

F. Saito, K. Tsuchiya, and M. Kotera, "An autopsied case of Parkinson's disease manifesting Shy-Drager syndrome," *Clinical Neurology*, vol. 32, no. 11, pp. 1238–1244, 1992.

M. Magalhaes, G. K. Wenning, S. E. Daniel, and N. P. Quinn, "Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson's disease—a retrospective comparison," *Acta Neurologica Scandinavica*, vol. 91, no. 2, pp. 98–102, 1995.

H. Braak, E. Ghebremedhin, U. Rüih, H. Bratzke, and K. Del Tredici, "Stages in the development of Parkinson's disease-related pathology," *Cell and Tissue Research*, vol. 318, no. 1, pp. 121–134, 2004.

D. S. Goldstein, Y. Sharabi, B. I. Karp et al., "Cardiac sympathetic denervation preceding motor signs in Parkinson disease," *Clinical Autonomic Research*, vol. 17, no. 2, pp. 118–121, 2007.

V. Milazzo, C. Di Stefano, S. Servo, M. Zibetti, L. Lopiano, and S. Maule, "Neurogenic orthostatic hypotension as the initial feature of Parkinson disease," *Clinical Autonomic Research*, vol. 22, no. 4, pp. 203–206, 2012.

S. J. Piha, J. O. Rinne, U. K. Rinne, and A. Seppanen, "Autonomic dysfunction in recent onset and advanced Parkinson's disease," *Clinical Neurology and Neurosurgery*, vol. 90, no. 3, pp. 221–226, 1988.

R. Sandyk and G. I. Awerbuch, "Dysautonomia in Parkinson's disease: relationship to motor disability," *International Journal of Neuroscience*, vol. 64, no. 1–4, pp. 23–31, 1992.

R. Martin, R. Manzanares, J. M. Moltó, T. Canet, C. Ruiz, and J. Matías-Guiu, "Cardiovascular reflexes in Parkinson disease," *The Italian Journal of Neurological Sciences*, vol. 14, no. 6, pp. 437–442, 1993.

D. Devos, M. Kroumová, R. Bordet et al., "Heart rate variability and Parkinson's disease severity," *Journal of Neural Transmission*, vol. 110, no. 9, pp. 997–1011, 2003.

A. Meseč, S. Sega, and T. Klauda, "The influence of the type, duration, severity and levodopa treatment of Parkinson's disease on cardiovascular autonomic responses," *Clinical Autonomic Research*, vol. 3, no. 5, pp. 339–344, 1993.

J. P. Wolf, M. Bouhaddi, F. Louisy et al., "Side-effects of L-dopa on venous tone in Parkinson's disease: a leg-weighing assessment," *Clinical Science*, vol. 110, no. 3, pp. 369–377, 2006.

S. Perez-Lloret, M. V. Rey, N. Fabre et al., "Factors related to orthostatic hypotension in Parkinson's disease," *Parkinsonism and Related Disorders*, vol. 18, no. 5, pp. 501–505, 2012.

I. O. Poon and U. Braun, "High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans," *Journal of Clinical Pharmacy and Therapeutics*, vol. 30, no. 2, pp. 173–178, 2005.

K. M. Rose, M. L. Eigenbrodt, R. L. Biga et al., "Orthostatic hypotension predicts mortality in middle-aged adults: the atherosclerosis risk in communities (ARIC) study," *Circulation*, vol. 114, no. 7, pp. 630–636, 2006.

G. C. Verwoert, F. U. S. Mattace-Raso, A. Hofman et al., "Orthostatic hypotension and risk of cardiovascular disease in elderly people: the Rotterdam study," *Journal of the American Geriatrics Society*, vol. 56, no. 10, pp. 1816–1820, 2008.
[95] K. M. Rose, D. Couper, M. L. Eigenbrodt, T. H. Mosley, A. R. Sharrett, and R. F. Gottesman, "Orthostatic hypotension and cognitive function: the atherosclerosis risk in communities study," *Neuroepidemiology*, vol. 34, no. 1, pp. 1–7, 2010.
[96] G. K. Kerr, C. J. Worringham, M. H. Cole, P. F. Lacheréz, J. M. Wood, and P. A. Silburn, "Predictors of future falls in Parkinson disease," *Neurology*, vol. 75, no. 2, pp. 116–124, 2010.
[97] L. M. Allcoock, R. A. Kenny, U. P. Mosimann et al., "Orthostatic hypotension in Parkinson's disease: association with cognitive decline?" *International Journal of Geriatric Psychiatry*, vol. 21, no. 8, pp. 778–783, 2006.
[98] A. D. Hohler, J. P. Zuzuáregui, D. I. Katz et al., "Differences in motor and cognitive function in patients with Parkinson's disease with and without orthostatic hypotension," *International Journal of Neuroscience*, vol. 122, no. 5, pp. 233–236, 2012.
[99] J. Idiaquez, E. E. Benarroch, H. Rosales, P. Milla, and L. Rios, "Autonomic and cognitive dysfunction in Parkinson's disease;" *Clinical Autonomic Research*, vol. 17, no. 2, pp. 93–98, 2007.
[100] K. R. Chaudhuri, D. G. Healy, and A. H. V. Schapira, "Nonmotor symptoms of Parkinson's disease: diagnosis and management;" *The Lancet Neurology*, vol. 5, no. 3, pp. 235–245, 2006.
[101] A. A. Ejaz, A. Kazory, and M. E. Heinig, "24-hour blood pressure monitoring in the evaluation of supine hypertension and orthostatic hypotension," *Journal of Clinical Hypertension*, vol. 9, no. 12, pp. 952–955, 2007.
[102] J. Senard and A. Pathak, "Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?" *Revue Neurologique*, vol. 166, no. 10, pp. 779–784, 2010.
[103] K. E. Lyons and R. Pahwa, "The impact and management of nonmotor symptoms of Parkinson's disease;" *The American Journal of Managed Care*, vol. 17, supplement 12, pp. S308–S314, 2011.
[104] K. Fujimoto, "Management of non-motor complications in Parkinson's disease;" *Journal of Neurology*, vol. 256, supplement 3, pp. S299–S305, 2009.
[105] S. Perez-Lloret and O. Rascol, "Dopamine receptor agonists for the treatment of early or advanced Parkinsons disease;" *CNS Drugs*, vol. 24, no. 11, pp. 941–968, 2010.
[106] S. Hawkins and B. J. Prout, "Postural hypotension and its management," *Practitioner*, vol. 226, no. 1365, pp. 420–426, 1982.
[107] G. Mostile and J. Jankovic, "Treatment of dysautonomia associated with Parkinson's disease;" *Parkinsonism and Related Disorders*, vol. 15, supplement 3, pp. S224–S232, 2009.
[108] K. L. Schoffer, R. D. Henderson, K. O'Maley, and J. D. O'Sullivan, "Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease;" *Movement Disorders*, vol. 22, no. 11, pp. 1543–1549, 2007.